---
title: "Charles Rhyee Reaffirms Buy on Medline as Price Target Cut to $45, Backed by Strong Cash Flow and 2027 Growth Outlook"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295354541.md"
description: "TD Cowen's Charles Rhyee maintains a Buy rating on Medline with a $45 price target, citing strong cash flows and an 11% growth outlook for 2027. Despite lowering the 2026 adjusted EBITDA guidance to $3.38B due to temporary issues and tariffs, Rhyee believes easing costs and new contract conversions justify the valuation. Morgan Stanley also recently assigned a Buy rating with a $48 target."
datetime: "2026-08-10T03:25:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295354541.md)
  - [en](https://longbridge.com/en/news/295354541.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295354541.md)
---

# Charles Rhyee Reaffirms Buy on Medline as Price Target Cut to $45, Backed by Strong Cash Flow and 2027 Growth Outlook

In a report released yesterday, Charles Rhyee from TD Cowen maintained a Buy rating on Medline, with a price target of $45.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Charles Rhyee has given his Buy rating due to a combination of factors tied to Medline’s earnings outlook and valuation. While he revised his price target to $45 after management lowered 2026 adjusted EBITDA guidance, he still sees the business generating solid cash flows, with 2026 adjusted EBITDA now modeled at $3.38B excluding significant tariff refund payments.

Rhyee also highlights that about half of the $200M reduction in 2026 EBITDA guidance stems from temporary issues, supporting his view that Medline can deliver robust growth in 2027, estimated at around 11%. As the company converts its sizable 2025 new contract signings into Medline-branded products, benefits from easing transitory costs, and ultimately implements price increases, he believes the shares can reasonably trade at roughly 20x his 2027 adjusted EBITDA forecast, justifying a Buy recommendation.

In another report released on August 6, Morgan Stanley also assigned a Buy rating to the stock with a $48.00 price target.

### Related Stocks

- [MDLN.US](https://longbridge.com/en/quote/MDLN.US.md)
- [TD.US](https://longbridge.com/en/quote/TD.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [Medline tallies tariff refunds as Q2 sales rise 11.6%](https://longbridge.com/en/news/296260871.md)
- [19:54 ETMDLN Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm](https://longbridge.com/en/news/296279958.md)
- [GIC Private reports $57.28 million Medline common share disposal](https://longbridge.com/en/news/296141799.md)
- [18:40 ETMDLN Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm](https://longbridge.com/en/news/295855493.md)
- [Medline completes prime vendor agreement implementation with Doctors Outpatient Surgery Center](https://longbridge.com/en/news/295859362.md)